[Intraperitoneal infusion therapy of MTX and 5-FU for advanced gastric cancer and its peritoneal metastasis]. 1995

S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.

We administered methotrexate (MTX) and 5-fluorouracil (5-FU) into the peritoneal cavity as chemotherapy after operation for advanced gastric cancer from a port implanted subcutaneously during the operation, every or every other week. It has been said that MTX tends to be kept in the peritoneal cavity, so the kinetics of MTX is important when it was administered there in. We investigated the concentrations of MTX in the peritoneal cavity and serum with infusion into the peritoneal cavity (IP), and compared it with intraarterial (IA) and intravenous (IV) administration. The results were the lower serum concentration of MTX in IP than in both IA and IV at 1-2 hours after infusion, but thereafter it was the same level in each group. The intraperitoneal concentration of MTX was lower than the detectable level at 24-48 hours after infusion. On the other hand, we investigated the side effects of this therapy, and only one of 20 cases given therapy many times had nausea and vomiting. So the intraperitoneal infusion therapy of MTX and 5-FU seemed to be safe.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010534 Peritoneal Neoplasms Tumors or cancer of the PERITONEUM. Peritoneal Carcinomatosis,Peritoneal Surface Malignancy,Carcinomatosis, Peritoneal,Malignancy, Peritoneal Surface,Neoplasm, Peritoneal,Peritoneal Carcinomatoses,Peritoneal Neoplasm,Peritoneal Surface Malignancies,Surface Malignancy, Peritoneal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
November 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
May 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
October 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
July 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
June 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
June 1983, Seminars in oncology,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
January 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
September 2006, Gan to kagaku ryoho. Cancer & chemotherapy,
S Takamatsu, and M Maruyama, and N Sugano, and M Katada, and M Ebuchi
February 2011, The journal of medical investigation : JMI,
Copied contents to your clipboard!